In this second round table discussion, experts from Switzerland and Germany discuss practice-changing studies in the fields of Head & Neck Tumors and Lung Cancer with the ASCO2020 original authors. The following authors are presenting their studies: Prof. Dr. Kevin Joseph Harrington The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, United Kingdom KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Prof. Dr. Martin Reck LungenClinic Grosshansdorf, Grosshansdorf, Germany Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. Prof. Dr. Joel Guigay Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, France TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). John Kuruvilla, MD (Dr.) Princess Margaret Cancer Centre, Toronto, ON, Canada KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.